Blocking TIM3 has shown to promote the activation of conventional DCs (cDC) in tumors [74], increase the responsiveness to cisplatin treatment (known to trigger the release of HMGB1) and the efficacy of DNA–based tumor vaccines in mouse models [73]. Here, HAVCR2 is linked to neoplasm.